SITC 2026: UT MD Anderson highlights advances in cancer immunotherapy
ABSTRACTS: 241, 566, 828, 931, 1180
Researchers from The University of Texas MD Anderson Cancer Center highlighted promising advances in cancer immunotherapy at the 2026 Society for Immunotherapy of Cancer (SITC) Annual Meeting. The presentations showcased early-phase clinical trials and preclinical studies exploring new approaches to treating advanced cancers, including solid tumors, brain cancer and melanoma. These studies offer...
Randomized trial finds targeting individual metastases in oligometastatic breast cancer does not improve survival
Oligometastatic cancer has spread beyond the original tumor to a limited number of sites Study tested whether treating all visible...
Fecal microbiota transplantation may improve immunotherapy-related colitis
Immunotherapy-related colitis is a potentially serious side effect of immunotherapy that can force patients to pause cancer treatment ...
Most patients with appendix cancer may avoid chemotherapy after surgery, study suggests
Researchers found fewer than 10% of patients experienced cancer recurrence after surgery
Chemotherapy after surgery was not associated with longer survival or lower relapse rates
Certain tumor types and genetic changes helped identify patients at higher risk of recurrence
Most patients with localized appendix cancer may be able to safely avoid chemotherapy after surgery, according to a new study from researchers at The University of...
KRAS-targeting drugs show promise for rare appendix cancer
KRAS is the most common genetic mutation in appendix cancer, occurring in approximately 80% of mucinous tumors, the most common subtype
KRAS-targeted...
ASCO: Targeted therapy combo nearly doubles time without disease progression for patients with advanced colorectal cancer
Cohort 3 of the BREAKWATER trial evaluated encorafenib plus cetuximab with FOLFIRI chemotherapy
Updated results demonstrate improved progression‑free...
ASCO: UT MD Anderson spotlights emerging precision therapies for rare and difficult-to-treat cancers
ABSTRACTS: 8510, 8008, 6009, 4520
Researchers at The University of Texas MD Anderson Cancer Center will present new findings at the...
Tumor markers in rare appendiceal cancer may predict treatment outcomes
Researchers monitored levels of common blood markers before and after surgery to remove cancer
Study found...
New simulation framework DKOsim advances CRISPR-based gene to gene interaction research
Double-CRISPR Knockout Simulation (DKOsim) is a computer-based “virtual lab” that simulates genomic experiments Studying...
UT MD Anderson opens new Colorectal Center to provide specialized care in healing environment
The University of Texas MD Anderson Cancer Center announced the opening of its new Colorectal Center, located on...